Cargando…

Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review

With an increasing aging population, the burden of age-related diseases magnifies. To alleviate this burden, geroprotection has been an area of intense research focus with the development of pharmacological interventions that target lifespan and/or healthspan. However, there are often sex difference...

Descripción completa

Detalles Bibliográficos
Autores principales: Knufinke, Marie, MacArthur, Michael R., Ewald, Collin Y., Mitchell, Sarah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249017/
https://www.ncbi.nlm.nih.gov/pubmed/37305228
http://dx.doi.org/10.3389/fragi.2023.1172789
_version_ 1785055473243783168
author Knufinke, Marie
MacArthur, Michael R.
Ewald, Collin Y.
Mitchell, Sarah J.
author_facet Knufinke, Marie
MacArthur, Michael R.
Ewald, Collin Y.
Mitchell, Sarah J.
author_sort Knufinke, Marie
collection PubMed
description With an increasing aging population, the burden of age-related diseases magnifies. To alleviate this burden, geroprotection has been an area of intense research focus with the development of pharmacological interventions that target lifespan and/or healthspan. However, there are often sex differences, with compounds mostly tested in male animals. Given the importance of considering both sexes in preclinical research, this neglects potential benefits for the female population, as interventions tested in both sexes often show clear sexual dimorphisms in their biological responses. To further understand the prevalence of sex differences in pharmacological geroprotective intervention studies, we performed a systematic review of the literature according to the PRISMA guidelines. Seventy-two studies met our inclusion criteria and were classified into one of five subclasses: FDA-repurposed drugs, novel small molecules, probiotics, traditional Chinese medicine, and antioxidants, vitamins, or other dietary supplements. Interventions were analyzed for their effects on median and maximal lifespan and healthspan markers, including frailty, muscle function and coordination, cognitive function and learning, metabolism, and cancer. With our systematic review, we found that twenty-two out of sixty-four compounds tested were able to prolong both lifespan and healthspan measures. Focusing on the use of female and male mice, and on comparing their outcomes, we found that 40% of studies only used male mice or did not clarify the sex. Notably, of the 36% of pharmacologic interventions that did use both male and female mice, 73% of these studies showed sex-specific outcomes on healthspan and/or lifespan. These data highlight the importance of studying both sexes in the search for geroprotectors, as the biology of aging is not the same in male and female mice. Systematic Review Registration: [website], identifier [registration number].
format Online
Article
Text
id pubmed-10249017
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102490172023-06-09 Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review Knufinke, Marie MacArthur, Michael R. Ewald, Collin Y. Mitchell, Sarah J. Front Aging Aging With an increasing aging population, the burden of age-related diseases magnifies. To alleviate this burden, geroprotection has been an area of intense research focus with the development of pharmacological interventions that target lifespan and/or healthspan. However, there are often sex differences, with compounds mostly tested in male animals. Given the importance of considering both sexes in preclinical research, this neglects potential benefits for the female population, as interventions tested in both sexes often show clear sexual dimorphisms in their biological responses. To further understand the prevalence of sex differences in pharmacological geroprotective intervention studies, we performed a systematic review of the literature according to the PRISMA guidelines. Seventy-two studies met our inclusion criteria and were classified into one of five subclasses: FDA-repurposed drugs, novel small molecules, probiotics, traditional Chinese medicine, and antioxidants, vitamins, or other dietary supplements. Interventions were analyzed for their effects on median and maximal lifespan and healthspan markers, including frailty, muscle function and coordination, cognitive function and learning, metabolism, and cancer. With our systematic review, we found that twenty-two out of sixty-four compounds tested were able to prolong both lifespan and healthspan measures. Focusing on the use of female and male mice, and on comparing their outcomes, we found that 40% of studies only used male mice or did not clarify the sex. Notably, of the 36% of pharmacologic interventions that did use both male and female mice, 73% of these studies showed sex-specific outcomes on healthspan and/or lifespan. These data highlight the importance of studying both sexes in the search for geroprotectors, as the biology of aging is not the same in male and female mice. Systematic Review Registration: [website], identifier [registration number]. Frontiers Media S.A. 2023-05-22 /pmc/articles/PMC10249017/ /pubmed/37305228 http://dx.doi.org/10.3389/fragi.2023.1172789 Text en Copyright © 2023 Knufinke, MacArthur, Ewald and Mitchell. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Aging
Knufinke, Marie
MacArthur, Michael R.
Ewald, Collin Y.
Mitchell, Sarah J.
Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
title Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
title_full Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
title_fullStr Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
title_full_unstemmed Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
title_short Sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
title_sort sex differences in pharmacological interventions and their effects on lifespan and healthspan outcomes: a systematic review
topic Aging
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249017/
https://www.ncbi.nlm.nih.gov/pubmed/37305228
http://dx.doi.org/10.3389/fragi.2023.1172789
work_keys_str_mv AT knufinkemarie sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview
AT macarthurmichaelr sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview
AT ewaldcolliny sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview
AT mitchellsarahj sexdifferencesinpharmacologicalinterventionsandtheireffectsonlifespanandhealthspanoutcomesasystematicreview